Skip to main content

Advertisement

SpringerLink
Log in

Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Prevention of deep vein thrombosis (DVT) is important in patients undergoing major orthopedic surgery. Although the detection of an elevated d-dimer level is useful for predicting DVT, it is not efficacious in postoperative patients being treated with anti-Xa agents. The soluble platelet glycoprotein VI (sGPVI) level is a marker of activated platelets, but not bleeding. Therefore, sGPVI levels are usually examined as a predictor of DVT in such patients. In the present study, 83 orthopedic patients were treated with 30 mg of edoxaban for prophylaxis of DVT. Fourteen patients developed DVT and 17 patients discontinued the prophylaxis due to decreased hemoglobin levels. Plasma levels of sGPVI in the patients were significantly higher after surgery than before surgery. On day 1, the sGPVI levels increased, while the platelet counts decreased. There were no significant differences in d-dimer, soluble fibrin, or FDP levels in orthopedic patients with and without DVT before surgery and on days 1, 4, and 8. Plasma sGPVI levels were significantly higher in the patients with DVT than in those without DVT on days 1 and 4. Plasma levels of d-dimer were significantly higher in patients with withdrawal than in those without. However, there were no significant differences in sGPVI levels between those with and without withdrawal. As d-dimer levels are known to increase in patients with withdrawal, this parameter is not useful for evaluating the risk of DVT in these patients. In contrast, the sGPVI level is not increased in those with withdrawal and may therefore be useful for evaluating the risk of DVT in postoperative patients treated with an anticoagulant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 1997;272:23528–31.

    Article  CAS  PubMed  Google Scholar 

  2. Leitinger B. Transmembrane collagen receptors. Annu Rev Cell Dev Biol. 2011;27:265–90.

    Article  CAS  PubMed  Google Scholar 

  3. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood. 2004;104:3611–7.

    Article  CAS  PubMed  Google Scholar 

  4. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007;5:1530–7.

    Article  CAS  PubMed  Google Scholar 

  5. Gardiner EE, Al-Tamimi M, Andrews RK, Berndt MC. Platelet receptor shedding. Methods Mol Biol. 2012;788:321–39.

    Article  CAS  PubMed  Google Scholar 

  6. Al-Tamimi M, Arthur JF, Gardiner E, Andrews RK. Focusing on plasma glycoprotein VI. Thromb Haemost. 2012;107:648–55.

    Article  CAS  PubMed  Google Scholar 

  7. Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, Hankey GJ, Berndt MC, Baker RI, Andrews RK. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke. 2011;42:498–500.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Tamimi M, Grigoriadis G, Tran H, Paul E, Servadei P, Berndt MC, Gardiner EE, Andrews RK. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood. 2011;117:3912–20.

    Article  CAS  PubMed  Google Scholar 

  9. Nurden P, Tandon N, Takizawa H, Couzi L, Morel D, Fiore M, Pillois X, Loyau S, Jandrot-Perrus M, Nurden AT. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost. 2009;7:1541–9.

    Article  CAS  PubMed  Google Scholar 

  10. Bigalke B, Stellos K, Weig HJ, Geisler T, Seizer P, Kremmer E, Pötz O, Joos T, May AE, Lindemann S, Gawaz M. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol. 2009;104:352–7.

    Article  CAS  PubMed  Google Scholar 

  11. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H, Ozaki Y. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993–6001.

    Article  CAS  PubMed  Google Scholar 

  12. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, Shin Y, Hirashima M, Ozaki Y. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 2010;285:24494–507.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Geerts WH, Heit JA, Clagett P, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest. 2001;119:S132–75.

    Article  Google Scholar 

  14. Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, Turpie AG, Gallus AS, Planès A, Passera R, Rouillon A, AIDA investigators. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3:2664–70.

    Article  CAS  PubMed  Google Scholar 

  15. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen, Colwell CW, Ray JG. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:338S–400S.

    Article  CAS  PubMed  Google Scholar 

  16. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Canadian Collaborative Group. Chest. 1998;114:115S–8S.

    Article  CAS  PubMed  Google Scholar 

  17. Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg. 1999;81-A:932–40.

    Google Scholar 

  18. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853–61.

    Article  CAS  PubMed  Google Scholar 

  19. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8:2458–68.

    Article  CAS  PubMed  Google Scholar 

  20. Sudo A, Wada H, Nobori T, Yamada N, Ito M, Niimi R, Hasegawa M, Suzuki K, Uchida A. Cut-off values of d-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery. Int J Hematol. 2009;89:572–6.

    Article  CAS  PubMed  Google Scholar 

  21. Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Matsumoto T, Shimokariya Y, Noma K, Yamada N, Uchida A, Nobori T, Sudo A. Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux. Int J Hematol. 2012;95:160–6.

    Article  CAS  PubMed  Google Scholar 

  22. Hasegawa M, Wada H, Wakabayashi H, Yoshida K, Miyamoto N, Asanuma K, Matsumoto T, Ohishi K, Shimokariya Y, Yamada N, Uchida A, Sudo A. The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. Clin Chim Acta. 2013;425:109–13.

    Article  CAS  PubMed  Google Scholar 

  23. Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettler W, Schmidt B, Schroeder HE. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost. 2003;89:228–34.

    CAS  PubMed  Google Scholar 

  24. Hosoka Y, Naitoh K, Honda M. Novel platelet activation marker and method for determination thereof, European Patent Application publication No. EP2000802 A1, published on December 10, 2007.

  25. Takayama H, Hosaka Y, Nakayama K. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Investig. 2008;118:1785–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Yamashita Y, Naitoh K, Wada H, Ikejiri M, Mastumoto T, Ohishi K, Hosaka Y, Nishikawa M, Katayama N. Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. Thromb Res. 2014;133:440–4.

    Article  CAS  PubMed  Google Scholar 

  27. Tsuji A, Wada H, Matsumoto T, Abe Y, Ota S, Yamada N, Sugiyama T, Sudo A, Onishi K, Nakatani K, Uchida A, Ito M, Suzuki K, Nobori T. Elevated levels of soluble fibrin in patients with venous thromboembolism. Int J Hematol. 2008;88:448–53.

    Article  PubMed  Google Scholar 

  28. Wada H, Matsumoto T, Yamashita Y, Hatada T. Disseminated intravascular coagulation: testing and diagnosis. Clin Chim Acta. 2014;436C:130–4.

  29. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009;20:143–9.

    Article  CAS  PubMed  Google Scholar 

  30. Bigalke B, Pötz O, Kremmer E, Geisler T, Seizer P, Puntmann VO, Phinikaridou A, Chiribiri A, Nagel E, Botnar RM, Joos T, Gawaz M. Sandwich immunoassay for soluble glycoprotein VI in patients with symptomatic coronary artery disease. Clin Chem. 2011;57:898–904.

    Article  CAS  PubMed  Google Scholar 

  31. Al-Tamimi M, Tan CW, Qiao J, Pennings GJ, Javadzadegan A, Yong AS, Arthur JF, Davis AK, Jing J, Mu FT, Hamilton JR, Jackson SP, Ludwig A, Berndt MC, Ward CM, Kritharides L, Andrews RK, Gardiner EE. Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood. 2012;2012(119):4311–20.

    Article  Google Scholar 

  32. Wurster T, Poetz O, Stellos K, Kremmer E, Melms A, Schuster A, Nagel E, Joos T, Gawaz M, Bigalke B. Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischemic stroke. Platelets. 2013;24:560–5.

    Article  CAS  PubMed  Google Scholar 

  33. Hatzipantelis ES, Pana ZD, Gombakis N, Taparkou A, Tzimouli V, Kleta D, Zafeiriou DJ, Garipidou V, Kanakoudi F, Athanassiou M. Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease. Int J Hematol. 2013;98:158–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a Grant-in-Aid from Mochida Pharmaceutical Co., Ltd, the Ministry of Health, Labour, and Welfare of Japan for Blood Coagulation Abnormalities and the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Conflict of interest

The study was funded by Mochida Pharmaceutical Co., Ltd, and the sGPVI ELISA system was provided by the company. KN contributed to obtaining the measurements of sGPVI but was not involved in interpreting the results. KN is an employee of Mochida Pharmaceutical Co., Ltd. All authors have no other COI to report.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan

    Takumi Aota, Yoshiki Yamashita & Naoyuki Katayama

  2. Biology Laboratory, Discovery Research, Mochida Pharmaceutical Co., Ltd., Shizuoka, Japan

    Katsuki Naitoh

  3. Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie-ken, 514-8507, Japan

    Hideo Wada

  4. Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan

    Noriki Miyamoto, Masahiro Hasegawa, Hiroki Wakabayashi, Kakunoshin Yoshida, Kunihiro Asanuma, Atsumasa Uchida & Akihiro Sudo

  5. Department of Blood Transfusion, Mie University Graduate School of Medicine, Tsu, Japan

    Takeshi Matsumoto & Kohshi Ohishi

  6. Central Laboratory, Mie University Graduate School of Medicine, Tsu, Japan

    Yuji Shimokariya

  7. Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, Japan

    Norikazu Yamada

  8. Clinical Research Support Center, Mie University Graduate School of Medicine, Tsu, Japan

    Masakatsu Nishikawa

  9. Mie University Graduate School of Medicine, Tsu, Japan

    Atsumasa Uchida

Authors
  1. Takumi Aota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsuki Naitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideo Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiki Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noriki Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masahiro Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroki Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kakunoshin Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kunihiro Asanuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kohshi Ohishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuji Shimokariya
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Norikazu Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masakatsu Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Naoyuki Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Atsumasa Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Akihiro Sudo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Wada.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aota, T., Naitoh, K., Wada, H. et al. Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. Int J Hematol 100, 450–456 (2014). https://doi.org/10.1007/s12185-014-1676-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1676-x

Keywords

Search

Navigation